US EditionFirst German Patient Receives HEMGENIX Gene Therapy for Haemophilia B
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
First German Patient Receives HEMGENIX Gene Therapy for Haemophilia B
In a groundbreaking development, the first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at Hannover Medical School. Developed by CSL Behring, HEMGENIX is the first gene therapy of its kind approved in Europe for adults with severe forms of the disorder and represents a significant advancement in addressing the genetic cause of haemophilia B. Christian Schepperle of Interessengemeinschaft Hämophiler e.…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
